+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study



Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study



Yearbook of Oncology 2006: 174-175




(PDF emailed within 0-6 h: $19.90)

Accession: 063492041

Download citation: RISBibTeXText

DOI: 10.1016/s1040-1741(08)70124-6


Related references

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. Journal of Clinical Oncology 23(3): 482-493, 2004

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 105(9): 3420-3427,3413, 2005

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 105(9): 3420-3427, 2004

Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 87(12): 4979-4989, 1996

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 23(36): 9234-9242, 2005

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. New England Journal of Medicine 331(14): 896-903, 1994

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. Journal of Clinical Oncology 22(21): 4290-4301, 2004

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Journal of Clinical Oncology 26(28): 4595-4602, 2008

Wilms tumor 1 (WT1) gene mutations predict poor outcome in adults with cytogenetically normal (CN) acute myeloid leukemia (AML): A cancer and leukemia group B (CALGB) study. 2007

A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 90(12): 4710-4718, 1998

Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 108(5): 1677-1683, 2006

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111(11): 5371-5379, 2008

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 26(28): 4603-4609, 2008

Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. Seminars in Oncology 14(2 Suppl 1): 25-31, 1987

An evaluation of modified high-dose cytarabine -containing postremission therapy in patients over age 60 years with acute myeloid leukemia Data from the Toronto Leukemia Study Group. British Journal of Haematology 117(Supplement 1): 20-21, 2002